Vanguard Global Advisers
TXMD icon

Vanguard Global Advisers’s TherapeuticsMD TXMD Stock Holding History

Vanguard Global Advisers’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Hold
4,937
– – ﹤0.01% 3468
2026
Q1 		$9.97K Buy
+4,937
New +$11.1K ﹤0.01% 3477

Other funds holding TXMD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's TXMD Position: Q2 2026 in Review

Vanguard Global Advisers held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 4,937 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

Vanguard Global Advisers first reported a position in TXMD in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Vanguard Global Advisers held 4,937 shares of TherapeuticsMD worth $10.9K as of Q2 2026.
  • Vanguard Global Advisers left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3468 holding.
  • Vanguard Global Advisers first reported a position in TherapeuticsMD in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.